







He Y-G, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers 
VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine 
provides insight into the viability of testing human C3d-based vaccines in 








© 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the 
CC BY license (http://creativecommons.org/licenses/by/4.0/).  
Licence 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 




A novel C3d-containing oligomeric vaccine provides insight into the
viability of testing human C3d-based vaccines in mice
Yong-Gang Hea, Isabel Y. Pappwortha, Andreas Rossbachd, Joshua Paulina, Tarirai Mavimbaa,
Christine Hayesa, Liudmila Kulikc, V.Michael Holersc, Andrew M. Knighta,b,1,
Kevin J. Marchbanka,1,⁎
a Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
b School of Biomedical Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
c Departments of Medicine and Immunology, University of Colorado, SOM, Denver, CO, USA
d Cardiff University, Heath Park, Cardiff, Wales, UK







A B S T R A C T
The use of C3d, the final degradation product of complement protein C3, as a “natural” adjuvant has been widely
examined since the initial documentation of its immunogenicity-enhancing properties as a consequence of
binding to complement receptor 2. Subsequently it was demonstrated that these effects are most evident when
oligomeric, rather than when monomeric forms of C3d, are linked to various test protein antigens. In this study,
we examined the feasibility of enhancing the adjuvant properties of human C3d further by utilizing C4b-binding
protein (C4BP) to provide an oligomeric arrayed scaffold fused to the model antigen, tetanus toxin C fragment
(TTCF).
High molecular weight, C3d-containing oligomeric vaccines were successfully expressed, purified from
mammalian cells and used to immunize groups of mice. Surprisingly, anti-TTCF antibody responses measured in
these mice were poor. Subsequently we established by in vitro and in vivo analysis that, in the presence of mouse
C3, human C3d does not interact with either mouse or even human complement receptor 2.
These data confirm the requirement to develop murine versions of C3d based adjuvant compounds to test in
mice or that mice would need to be developed that express both human C3 and human CR2 to allow the testing
of human C3d based adjuvants in mouse in any capacity.
1. Introduction
Whilst it has been established for 40 years that complement (C)
plays an important role in both initiating and shaping adaptive im-
munity (Pepys, 1972, 1974), it was not until the identification and
characterization of B cell complement receptor 1 (CR1; CD35) and 2
(CR2; CD21) expression [reviewed in (Cooper et al., 1988; Hourcade
et al., 1989)], that the molecular basis for this was fully understood
(Fearon and Carter, 1995; Hebell et al., 1991). CR1 and CR2 are en-
coded separately from two linked genes in man, whilst in the mouse
both receptors are encoded from a single locus, Cr2, as a result of al-
ternate splicing (Holers et al., 1992; Kurtz et al., 1990). On B cells, CR1
contributes to the degradation of C3b to iC3b to C3c and C3d,g in co-
operation with factor I (Hourcade et al., 1989). C3d,g remains surface-
bound, where further proteolytic cleavage results in the generation of
the C3d fragment: both forms are ligands for CR2 (Law and Dodds,
1997), also found on the B cell plasma membrane. The generation of
Cr2 gene knockout mice (along with other key C component knockout
animals) confirmed the essential roles that C and CRs play in adaptive
immune responses (Ahearn et al., 1996; Molina et al., 1996).
It has been clear for some time that many components of the innate
immune system act to activate and enhance the adaptive immune re-
sponse, and can therefore be considered to be “natural” adjuvants
(Morgan et al., 2005). C3d is one such component. This was first
documented when multiple copies of mouse (m)C3d, in a linear trimer,
were attached to a soluble antigen, and shown to enhance antigen-
specific responses in mice up to 10,000 fold (Dempsey et al., 1996);
potentially being more potent than complete Freund’s adjuvant.
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Unsurprisingly therefore, a number of approaches using C3 breakdown
fragments as natural adjuvants have followed (reviewed by (Toapanta
and Ross, 2006)). Indeed, the high degree of amino acid sequence
homology between human (h) and mC3d (84.1%) suggested that hC3d-
based vaccines could also be examined in mice. Furthermore studies
showed that hC3 breakdown fragments induced cell cycle regulation
(Melchers et al., 1985,1986) and subsequent activation (Erdei et al.,
1985) of mouse B cells. In addition, polymerised hC3dg (tetramers to
20mers) was shown to be a potent activator of human B cells (Carter
and Fearon, 1989) and bound readily to recombinant hCR2 or mCR2
expressed by K562 cells, implying a conserved binding site and func-
tional homology across species with respect to C3dg binding (Martin
et al., 1991; Molina et al., 1991). However, not all studies using the
mC3d linear trimer have demonstrated enhanced antigen-specific im-
mune responses (Lee et al., 2005; Suradhat et al., 2001). In addition, the
mode of action of the C3d trimer is still not clear, with adjuvant
properties being detected in mice in the absence of mCR2, indicating
that novel receptors/interactions may exist (Lee et al., 2005; Haas et al.,
2004; De Groot et al., 2014). Thus, the potential for the C3d linear
trimer as a natural adjuvant for humans has been undermined sig-
nificantly. However, many of these unexpected findings with this
somewhat artificial form of C3d may reflect the synthetic nature of the
linear trimer format, rather than a true reflection of the natural ad-
juvant effect of C3d/g that physiologically exists as an oligomeric
“coat” on antigen surfaces.
We therefore decided to investigate whether multiple copies of C3d
arrayed in an oligomeric format (using the natural C4BP oligomerisa-
tion domain), rather than linked as a linear chain, would function as an
improved adjuvant. Herein, we provide new evidence that hC3d, even
when arrayed with C4BP, does not enhance antigen-specific immune
responses as surprisingly hC3d does not bind to mCR2 or even to hCR2
in the presence of mC3(/d). This finding clearly demonstrates the dif-
ficulty in testing hC3d-based adjuvants in the mouse. Alternative ap-
proaches to combat this include the development of wholly murine
versions of such constructs or the development of mice with a fully
humanised complement system (hC3 and hCR2), or molecular ad-
juvants designed to activate complement appropriately in multiple
species.
2. Materials and methods
2.1. Cells
The Chinese hamster ovary (CHO) cell line and human B cell line
Raji (expressing high levels of CR2 (Lambris et al., 1981)), were ob-
tained from Sigma, UK (products 85050302 and 85011429, respec-
tively). The CD19+ve, CR2−ve, mouse B cell line CH27, and transfec-
tants expressing mCR2 (CH27.mCR2), a tetanus toxin C fragment
(TTCF)-specific BCR (CH27.TTCF-BCR) or mCR2 and a TTCF-specific
BCR (CH27.mCR2/TTCF-BCR), previously described (Barrault and
Knight, 2004), were maintained in the presence of 0.75 mg/ml G418+/
− 300 ng/ml purinomycin, 0.3 mg/ml hygromycin B.
2.2. Generation and expression of recombinant vaccines and controls
Plasmid pDR2ΔEF1α (Charreau et al., 1994), containing the
hC4BPα chain, short consensus repeats (SCRs) 5–8 and the oligomer-
ization domain (P04003; amino acids (aa)248-548 of the mature pro-
tein), was obtained from C. Harris (Newcastle University, UK). Using
standard PCR-based cloning techniques DNA encoding the CD33 signal
peptide (MPLLLLLPLLWAGALAMD) was cloned into this vector with a
short linker containing restriction enzyme sites flanking a (his)tidine
tag to allow for further cloning and in-frame fusion with C4BP to
generate phC4BP. Next, hC3d (P01024; aa 1001-1303 of pre-pro C3;
with the 9th cysteine replaced by serine to remove a free sulfhydryl)
was PCR cloned and incorporated in-frame between the CD33 and
histag regions, generating phC3d-hC4BP. hCR2 (SCR1-4)-Fc, native
hC3d (containing 9th cysteine)-Fc, hC3dg (aa 955-1303)−Fc as well as
Cys to Ser variants of these, mCR2 (SCR1-4)-Fc and mC3d-Fc constructs
were also generated using PCR cloning utilizing a pDR2EF1α plasmid
containing human IgG1 Fc (gift of B. Spiller, Cardiff University, UK).
Recombinant TTCF encoding 444 amino acids of the mature TTCF from
the 7th amino acid (Hewitt et al., 1997) was PCR cloned from the
prokaryotic expression vector pET-16b with removal of the stop codon
to allow read through into hC4BP sequence generating phC3d-TTCF-
hC4BP. Finally, pTTCF-hC4BP was created by PCR cloning and insertion
of the TTCF product 3′ of the histag in phC4BP. All plasmids were
Sanger sequenced and transfected into CHO cells using the JetPEI re-
agent according to the manufacturer’s (Polyplus transfection) instruc-
tions. Inclusion of hygromycin B (600 μg/ml) and limiting dilution al-
lowed the selection of clonal transfectants. Recombinant proteins were
purified from tissue culture supernatant using immobilized metal ion
affinity chromatography, essentially as described for TTCF (Hewitt
et al., 1997), except 5 mM imidazole was used in the binding buffer.
2.3. Mice
All mice used in this study are on the C57BL/6 (B6) genetic back-
ground with or without the transgenes and/or genetic deletions de-
scribed below.
hCR1tg.hCR2tg.Cr2−/− mice (Pappworth et al., 2012) and
hCR2tg.C3−/− mice (Twohig et al., 2007) were routinely confirmed by
PCR and immunoblot. All mice used were age and sex matched litter-
mates from colonies maintained at Newcastle University or purchased
(B6) from Harlan (UK). All experiments were performed under the
terms of Animals (Scientific Procedures) Act 1986 and were authorized
by the Secretary of State, Home Office, UK.
2.4. Preparation and immunization of protein vaccines
Animals were immunized with molar equivalent doses of antigen/
construct standardized on 5 μg TTCF in sterilized PBS buffer. TTCF was
also precipitated on alum according to (Ghosh et al., 1996; Adkins
et al., 2000). The pellet was resuspended in PBS to achieve a final
concentration 500 μg/ml alum-TTCF. Animals were immunized by
intra-peritoneal (IP) injection and boosted with identical dose/antigen/
route at day 28. Blood was collected prior to immunization (day 0) and
then weekly until day 42.
2.5. Antibodies
Purified, biotin and allophycocyanin (APC) conjugated mAb 171
(mouse anti-hCR2, IgG1 isotype) (Guthridge et al., 2001a,b); biotin
mAb 7E9 (rat, anti-mCR2, IgG2a) (Kinoshita et al., 1988), biotin and
purified 10G5 (mouse, IgG1 anti-TTCF, (Antoniou and Watts, 2002))
and mouse IgG1 isotype control were produced following standard
methods. 2.4G2 (rat, anti-mCD16/mCD32, “Fc Block”), fluorescein
isothiocyanate (FITC) or PerCP conjugated RA3-6B2 (rat, anti-mCD45R,
B220), FITC conjugated species anti-hCD19 were obtained from Phar-
mingen (BD, Oxford, UK). Goat, anti-mouse IgG-HRPO; goat, anti-rabbit
IgG − HRPO; donkey, anti-sheep IgG-HRPO conjugated anti-IgM or
IgG, streptavidin-FITC and −PE were obtained from Jackson Im-
munoresearch Laboratories (Stratech Scientific, UK). Rabbit, anti-hC3d
and sheep, anti-hC4BP were purchased from Dako, UK and Abcam, UK
respectively.
2.6. ELISA
To detect the presence of recombinant proteins in CHO culture su-
pernatant (s/n) or for measurement of anti-TTCF Ig responses, flat-
bottom 96 well ELISA plates (Thermo Vinyl) were coated with un-
diluted s/n or 0.1 μg TTCF (in carbonate coating buffer (pH 9.6)),
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respectively, and incubated at 4 °C overnight. All plates were washed
3 x with PBS-0.05% Tween20 (wash buffer) and with 1% BSA/0.05%
Tween20 (blocking buffer) in PBS for 2 h at room temperature (RT). For
the detection of bound protein, primary antibodies were diluted 1/
10,000 for the polyclonals or 1/1000 for 10G5. For the detection of
anti-TCCF Ig, mouse serum was diluted in blocking buffer (1/50)) and
compared to blocking buffer containing mouse anti-TTCF monoclonal
antibody 10G5. Plates were then incubated for 1 h at RT and then
washed 3x and blocked for additional 2 h as above. Appropriate Ig-
HRPO secondary antibody was incubated in blocking buffer for 1 h at
RT. Plates were washed twice with wash buffer and finally two times
with PBS. Freshly made 3,3,5,5′-Tetramethylbenzidine (TMB) substrate
was added to each well and the reaction stopped using 10% H2SO4.
OD450 nm was measured using SpectraMAX 190 microplate reader
(Molecular Devices, USA).
2.7. Flow cytometry
Mouse splenocytes were isolated as described in (Birrell et al.,
2005). Human peripheral blood mononuclear cells (PBMC) were iso-
lated from healthy volunteers using Lympholyte-H Cell Separation
Media (Cedarlane Labs, Canada), according to manufacturer’s instruc-
tion and in accordance with local ethical guidance.
Splenocytes (following red blood cell lysis) or cell lines were washed
in PBS containing 1% fetal calm serum (flow buffer) and then re-sus-
pended in 10 μg/ml Fc Block for 15 min on ice. Cells were subsequently
washed and re-suspended in flow buffer containing primary antibody
(Ab) (0.1–3 μg/ml) for 30 min on ice. Cells were then washed 3 times in
flow buffer and incubated with the appropriate secondary reagent for
30 min. Cells were washed and resuspended in flow buffer containing
1% formaldehyde. Samples were analysed using a FACS Canto ™ II (BD,
Oxford, UK) and FlowJo (LLC, Ashland, OR, USA) or Cyflogic (v 1.2.1,
free ware).
2.8. Biacore
Chips were purchased from GE Healthcare and all buffers were
0.2 μm filtered prior to use. Immobilisation: standard amine coupling
Fig. 1. Recombinant constructs and protein production.
a) Tissue culture supernatant collected from CHO cells expressing constructs, diagrammatically indicated to left of blot, was prepared in reducing sample buffer and loaded on a 10% SDS-
PAGE gel before blotting to nitrocellulose. Predicted monomer constructs: hC3d-TTCF-hC4BP: 124.2 kDa, TTCF-hC4BP: 89.5 kDa, hC3d-hC4BP: 72.1 kDa and hC4BP: 38.1 kDa were
detected. (b) hC3d-TTCF-hC4BP supernatant in non-reducing (NR) and reducing (R) sample buffer was separated on 5% SDS-PAGE, transferred using a modified glycine-methanol
transfer buffer containing 0.1% SDS at 35 V overnight followed by 100 V for 1hr. In both panels, proteins were detected using sheep anti-hC4BP antibody followed by donkey anti-sheep
IgG-HRPO. The migration of protein size markers are indicated on the right of each blot. Predicted conformation is illustrated diagrammatically either side of blots.
ELISA plate wells were coated with undiluted tissue culture supernatants from CHO cell transfectants (as indicated on x axis). Plate-bound constructs were detected with rabbit anti-hC3d
followed by goat anti-rabbit HRPO (c), anti-TTCF (mAb 10G5) followed by goat anti-mouse HRPO (d), sheep anti-hC4BP followed by donkey anti-sheep HRPO (e). Supernatants collected
from untransfected CHO cells were used to calculate relative units (RU). Panel (f) shows coomassie blue staining following SDS-PAGE analysis of approximately 1–2ug of affinity purified
recombinant proteins. All results shown are representative of several similar experiments.
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reactions were carried out at 30 μl/min. Ligands were prepared in
10 mM sodium acetate at a final concentration of 2 μg/ml.
Immobilisation was optimised using the pH scouting wizard program
using sodium acetate at pH 5.4, 5.0, 4.6, 4.2 and 3.7. The im-
mobilisation wizard controlled the coupling reactions. Optimal reaction
conditions were set up using equal volumes of N-hydroxysuccinimide
(NHS; 100 mM) and 1-ethyl-3-(dimethylaminopropyl)carbodiimide
(EDC; 40 mM) the ligand in the appropriate buffer, 1 M ethanolamine-
HCl pH 8.5 and 50 mM NaOH. The coupling was automatically termi-
nated when the response unit (RU) target was reached. Typically, flow
cell one (FC1) was left blank to act as control flow cell and only re-
ceived NHS/EDC and 1 M ethanolamine-HCl pH 8.5. The dextran ma-
trix in FC2 was activated with NHS/EDC, followed by ligand.
Remaining free binding sites in the matrix were blocked with 1 M
ethanolamine-HCl pH 8.5. Binding analysis was carried out im-
mediately after coupling. Prior to loading of the samples, flow was al-
lowed to stabilise for one minute. Analyte concentrations were blank
buffer control (HBS-EP+; GE Healthcare, UK), 0.195 nM, 0.39 nM,
0.78 nM, 1.56 nM, 3.125 nM, 6.25 nM 12.5 nM, 25 nM, 50 nM.
Analytes were injected in triplicate for 360 s. The injection was changed
from sample to buffer and dissociation was monitored for 240 s.
Typically the flow path was FC1 followed by FC2, which allowed sub-
traction of any secondary interactions with the dextran matrix. Chip
surfaces were regenerated with two brief pulses of 0.5 M NaCl for 30 s.
Results were analysed using the BIAevaluation Software version 4.1.
Single flow cells were analysed following blank flow cell background
subtraction (e.g. FC2-FC1). Curves were aligned by y-axis transforma-
tion and values obtained for buffer controls were subtracted from the
curve to compensate for buffer-surface interactions. Sensorgram data
was analysed with a steady state affinity model. Good fits were in-
dicated by low residuals and χ2 values (< 5) as calculated by the
evaluation software.
3. Results
3.1. Design and production of recombinant hC3d − TTCF multimeric
vaccines
Taking into account previous oligomerisation approaches (Libyh
et al., 1997; Christiansen et al., 2000), we used PCR to join cDNAs such
that an N-terminal hC3d was fused to the well characterised model
antigen tetanus toxin C fragment (TTCF), followed by SCRs 5–8 (to act
as spacers) and the C-terminal oligomerisation domain from hC4BPα
chain (hC3d-TTCF-hC4BP). Various hC4BPα chain-containing control
proteins were also generated (Fig. 1a). The presence of the various
fusion proteins in the supernatants of CHO transfectants was confirmed
using Western blotting following reducing (Fig. 1a, b) and non-reducing
SDS PAGE (Fig. 1b). Using ELISA, we also confirmed both the presence
and integrity of the individual domains in each fusion protein
(Fig. 1c–e). Collected supernatants containing each fusion protein were
subjected to immobilized metal ion affinity chromatography and elu-
ates assessed using SDS-PAGE (Fig. 1f).
3.2. hC3d-TTCF-hC4BP binds to RAJI and primary human B cells through
interaction with hCR2
Next, we confirmed that the hC3d-TTCF-hC4BP candidate vaccine
would specifically bind to hCR2 expressed on B cells. hCR2+ve Raji B
cells were incubated with the various fusion proteins in the presence or
absence of an hCR2 blocking antibody (mAb 171, (Guthridge et al.,
2001a,b)). Both hC3d-TTCF-hC4BP and hC3d-hC4BP (but not hC4BP)
fusion proteins bound specifically to hCR2 (Fig. 2a). Using CD19 to sort
B cells from hPBMC, we also found that specific binding of the various
biotinylated hC4BP constructs to B cell CR2 was also dependent on the
presence of hC3d (Fig. 2b).
3.3. hC3d-TTCF-hC4BP does not induce significant anti-TTCF antibody
production in mice
Having established both antibody and receptor binding for the
various domains in the hC3d-TTCF-hC4BP fusion protein, and following
several previous reports that document hC3d interaction with mouse
(m) CR1/2 (Melchers et al., 1985,1986; Erdei et al., 1985; Molina et al.,
1991), we next tested the ability of hC3d-TTCF-hC4BP to act as an ef-
fective vaccine in mice. Mice were immunized with hC3d-TTCF-hC4BP,
alongside others immunized with molar equivalents of TTCF pre-
cipitated with the conventional adjuvant alum, or with TTCF prepared
in saline only. Following initial immunizations, all mice were boosted
at day 28 (using identical antigens to the primary immunization), and
then sera were collected weekly up to 42 days. Fig. 3 shows the levels of
anti-TTCF IgG present in the sera collected from the various groups of
mice. Somewhat surprisingly, immunization with the hC3d-TTCF-C4BP
fusion protein resulted in the detection of very low levels of anti-TTCF
IgG. Levels were comparable to those detected in the serum of mice
immunized with TTCF in saline during the primary response but mice
receiving hC3d-TTCF-C4BP fusion protein showed even lower levels of
TTCF-specific IgG than those animals that received TTCF in saline fol-
lowing the day 28 boost. Anti-TTCF IgG levels in those mice immunized
with alum-TTCF were significantly higher than those detected in mice
immunized with either the hC3d-TTCF-C4BP fusion protein or re-
combinant TTCF in saline. In order to rule out the delivery route and
antigen having a bearing on these results, we also carried out experi-
ments using hC3d-hen egg lysozyme (HEL)-C4BP fusions via in-
tradermal and intramuscular DNA as well as subcutaneous protein in-
jections. Again, the immune response to the hC3d – Antigen-C4BP
vaccines was poor (suppl. data Fig. 1–5, Suppl. Table 1).
3.4. hC3d-TTCF-C4BP does not bind to mCR2
Our finding that mice immunized with hC3d-TTCF-C4BP showed
very low levels of TTCF-specific IgG, led us to re-evaluate the reported
interactions of hC3d with mCR2 (Melchers et al., 1985, 1986; Erdei
et al., 1985; Molina et al., 1991). For this, we firstly utilized previously
generated transfectants of the mCR1/2 negative mouse B cell line
CH27, which expressed combinations of mCR2 and a TTCF-specific,
hIgG1 BCR (Barrault and Knight, 2004). Fig. 4 shows that biotinylated
hC3d-TTCF-C4BP bound those CH27 transfectants expressing a TTCF-
specific BCR (CH27.mCR2/TTCF-BCR and CH27.TTCF-BCR; Fig. 4a,
right panel) and that binding to both these transfectants was inhibited
by prior incubation with recombinant TTCF protein (Fig. 4b, left panel).
In addition, as expected hC3d-TTCF-C4BP did not bind to untransfected
CH27B cells (Fig. 4a), but nor was it seen to bind to CH27B cells ex-
pressing just mCR2 (CH27.mCR2), although mCR2 expression was
confirmed by anti-mCR2 staining (Fig. 4a, left panel). This was also
confirmed by the finding that hC3d-TTCF-C4BP binding to
CH27.mCR2/TTCF-BCR cells was not inhibited in the presence of a
blocking anti-mCR2 mAb (Fig. 4b, right panel). These finding indicate
that hC3d-TTCF-C4BP binding to CH27.mCR2/TTCF-BCR cells could be
solely attributed to TTCF/BCR interactions and that hC3d-TTCF-C4BP
unexpectedly does not bind mCR2.
To ensure that the lack of hC3d-TTCF-C4BP binding to mCR2 was
not just a feature of the recombinant C3d in the fusion protein, we next
measured the binding of native hC3d purified from human serum, along
with an alternative recombinant form of hC3d, to soluble mCR2 and
hCR2 using surface plasmon resonance (SPR). As seen in Fig. 5, we
found that a hCR2 (SCR 1-4)-Fc construct bound readily to immobilized
serum-derived hC3d under physiological salt conditions with an ap-
parent KD of 10.63±0.22 nM; (supplemental Table 3, Fig. 5a). This is
significantly (> 10 fold) higher than that noted in previous studies
using monomeric C3d and recombinant monomeric hCR2 (SCR1-2, 1-4
or 1-15) either as ligand or analyte with low salt conditions (50 mM)
that were deemed to provide optimal binding in this context (Asokan
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et al., 2006 Guthridge et al., 2001a,b; Sarrias et al., 2001). In contrast to
the strong binding of hCR2-Fc to immobilized hC3d, use of mCR2-Fc as
the analyte showed no binding to hC3d (Fig. 5b) above that seen with
an irrelevant Fc fusion protein (Fig. 5c), supporting the flow cytometry
data using CH27 cells expressing mCR2 (Fig. 4). We also extended this
analysis to evaluate the binding of a number of different hC3d variants
(i.e hC3d, a Cys to Ser variant of hC3d(s), hC3d with the g fragment
attached and a Cys to Ser hC3d,g (s) variant; all in Fc fusion form) to
hCR2 − Fc. As seen in Fig. 5h, we found that hCR2-Fc bound to im-
mobilized hC3d,g (s) with the highest affinity (2.6+/−0.22 nM), in
fact, hCR2–Fc bound better to all hC3d − Fc constructs than it did to
monomeric hC3d (Fig. 5d–g). Thus, whilst there were marginal differ-
ences in hC3d(g) or mutated hC3d binding to hCR2 SCR1-4 these data
confirm that recombinant hC3d-TTCF-C4BP failed to bind mCR2 as did
recombinant monomeric hC3d in contrast to that reported previously
(Melchers et al., 1985,1986; Erdei et al., 1985; Molina et al., 1991).
Interestingly, we also demonstrated that hCR2-Fc bound mC3d − Fc
immobilized on the chip with an affinity of 1.47±0.47 nM, which was
4 fold higher than the affinity measured for the interaction of hCR2-Fc
with hC3d-Fc immobilized on the chip surface.
3.5. hC3d-TTCF-C4BP only binds hCR2 expressed by transgenic mouse
splenic B cells isolated from C3−/− animals
As a result of our demonstration that hC3d-TTCF-C4BP (along with
monomeric hC3d) does not bind mCR2, we re-examined the ability of
the hC3d-TTCF-C4BP candidate vaccine to enhance anti-TTCF antibody
production following the immunization of transgenic mice expressing
hCR2. Using an essentially identical immunization and boost protocol
to that shown in Fig. 3, we immunized groups of> 5 animals from two
independent lines of hCR2 transgenic mice (Marchbank et al., 2002;
Kulik et al., 2011) with hC3d-TTCF-C4BP, TTCF-alum and TTCF in
saline. As before, the levels of TTCF-specific IgG measured in the sera of
these mice (suppl. data Figs. 6, suppl. Table 4) were essentially the
same as those shown previously for non-transgenic mice (Fig. 3). To
explore possible reasons to explain the lack of enhanced TTCF-specific
antibody in hCR2 transgenic mice, we carried out further binding
analysis with ex-vivo B cells isolated from either B6 non-transgenic, or
hCR1/2 transgenic mice. Similar to that seen with mouse B cell lines
(Fig. 4), hC3d-TTCF-C4BP did not bind to B cells isolated from B6 mice
(Fig. 6b). In addition, in contrast to that seen with human PBMC or
Fig. 2. hC3d-containing constructs bind to B cells via hCR2.
a) Raji cells were incubated with mAb 171 (hCR2 block, black line) or buffer alone (dark grey line) followed by hC3d-TTCF-hC4BP, hC3d-hC4BP and hC4BP. Bound constructs were
detected with sheep anti-hC4BP followed by PE conjugated donkey anti-sheep IgG. The filled light grey histogram indicates the level of background staining from the sheep anti-C4BP plus
secondary on cells treated with mAb 171 (but no construct) indicating no cross-reactivity of the secondary with the block (b). Isolated human PBMC cells from healthy volunteers (n = 4)
were stained with anti-hCD19-FITC to label B cells and were incubated with PBS (left column), mAb 171 (middle column), or TTCF (right column) prior to incubation with biotinylated
hC3d-TTCF-hC4BP, hC3d-hC4BP and hC4BP followed by SA-APC. 10,000 events were collected and results are representative of several experiments.
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human B cell lines (Fig. 2), Fig. 6b also shows that hC3d-TTCF-C4BP
also fails to bind to mouse B cells isolated from hCR2 transgenic mice,
despite their expression of hCR2 (Fig. 6a). To examine a possible reason
for this discrepancy, and in light of the increased binding of mC3d to
hCR2 in SPR analysis, we also examined the binding of hC3d-TTCF-
C4BP to B cells isolated from hCR2 transgenic mice that had been
crossed with mice lacking C3 (C3−/−). Similar to that seen with both
human B cell lines and PBMC (Fig. 2), Fig. 6b shows clearly that hC3d-
TTCF-C4BP does specifically bind to hCR2 expressed by B cells isolated
from hCR2 transgenic mice that lack C3 (hCR2/C3−/−).
4. Discussion
The key role played by complement in enhancing the adaptive im-
mune response is now well accepted. Over 40 years ago, the seminal
studies by Pepys et al. using C3 activating/depleting agents including
cobra venom factor and zymosan clearly demonstrated intact C3
function was important for the T-dependent response to various anti-
gens including sheep red blood cells and ovalbumin (Pepys, 1972,
1974). A refined molecular mechanism explaining this effect was es-
tablished by Fearon and colleagues(Fearon and Carter, 1995) who then
exploited this knowledge and established that multiple copies of C3d, in
a linear trimer, could enhance antigen-specific responses up to 10,000
fold (Dempsey et al., 1996). However, the initial potential of trimeric
C3d, as a highly potent molecular adjuvant, has not been realized and
Fig. 3. Direct in vivo comparison of the adjuvant effects of hC3d with the conventional
adjuvant alum.
Three groups (n = 4) of mice were immunized intra-peritoneally with hC3d-TTCF-
hC4BP/saline (circles); TTCF/Alum (squares) or TTCF/saline (triangles) containing TTCF
molar equivalents of 5 μg/animal, and boosted at day 28 (arrow) following initial im-
munization. Serum was collected on the days indicated and analysed for the presence of
anti-TTCF IgG by ELISA. Average values (relative units (RU))± SD are shown. One-way
ANOVA Tukey’s HSD test was used to define significance levels at 95% confidence (*
p < 0.05, ** 0.01 and *** 0.001).
Fig. 4. Recombinant hC3d-TTCF-hC4BP binds CH27 via TTCF specific BCR instead of mCR2.
a) Untransfected CH27B cells and various CH27 transfectant clones were incubated with biotinylated anti-mCR2 monoclonal antibody 7E9 (left panel) or biotinylated hC3d-TTCF-hC4BP
(right panel). Following the addition of SA-PE, fluorescence intensity was measured and histograms displayed using FlowJo. (b). Binding of biotinylated hC3d-TTCF-hC4BP to
CH27.TTCR-BCR and CH27.mCR2/TTCF-BCR clones in the presence or absence of TTCF and the mCR2 blocking antibody 7G6. Binding was detected with SA-PE and histograms were
overlapped using FlowJo. 10,000 cells were collected.
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the reason(s) for this remain(s) unclear. One possible explanation is that
the artificial linear trimer structure, when attached to the majority of
test antigens, fails to represent naturally opsonised antigen, and con-
sequently does not provide sufficient CR cross-linking for a functional
threshold to be reached. It is therefore possible that attaching more C3d
to test antigens could overcome this limitation leading to enhanced
adjuvant activity. In order to test this hypothesis, in this study we have
attached C3d via the natural oligomerization domain from hC4BP to a
test antigen to generate C3d − Ag multimers. Our analysis of the
product formed from this construct clearly demonstrates that high order
multimers are successfully produced and can be purified from mam-
malian cell cultures. Importantly, we also demonstrate that both the
test antigen and C3d components within these multimers are likely
folded correctly (as expected from expression in a mammalian cell line
compared with other forms of bio-production) as evidenced by the fact
that the individual domains within the multimer retain specific binding
to their appropriate receptors expressed on immortalized B cell lines as
well as primary human B cells. Despite these properties however, the
ability of two versions of this prototype vaccine (HEL and TTCF) to
enhance antigen-specific immune responses in mice was found to be
very poor.
Following further investigations we, somewhat surprisingly, estab-
lished that the hC3d component of this construct, along with purified
hC3d, does not bind mCR1/2. This finding apparently contradicts stu-
dies using polymerised human complement C3dg (pC3dg) and its
specific binding to COS and K562 cells expressing recombinant mCR2
(Martin et al., 1991). These data were also apparently supported by
independent experiments using erythrocytes coated with antibody and
human complement (EAC3d) binding murine AJ9 B cells, albeit less
well than human B cells (Fingeroth et al., 1989) and where EAC3d,g
bound to the surface of K562 cells expressing recombinant mCR2 which
was blocked by mAb 7G6 (Molina et al., 1991). They also reported that
glutaraldehyde-cross-linked hC3d,g bound both recombinant mCR2 and
hCR2 with almost identical kD of 4.6 nM (Molina et al., 1991). Our SPR
analysis, with hC3dg −Fc and hCR2 confirm a similar binding affinity
(kD of 3.1–5.1 nM) but in contrast we did not detect any interaction
between immobilized hC3d, either as monomer or as an Fc-fusion
product, with mCR2-Fc (Fig. 5). This finding is also supported by our
studies using recombinant multimeric hC3d and mouse B cell lines or
splenic B cells (Figs. 4 & 6).
Using purified and recombinant proteins in the SPR experiments
under physiological salt conditions, along with the flow cytometric
analysis of mouse B cells, we conclude with considerable confidence
that the lack of binding of hC3d to mCR2 detected in these experiments
represents the in vivo setting, and that unknown factors may have in-
fluenced the studies using recombinant mouse CR2 expressed on K562
(Martin et al., 1991; Molina et al., 1991). In the case of Martin et al., as
the molecule expressed was a hybrid of hCR2 and the 2 NH-terminal
SCRs of mCR2 it is possible highly polymerised hC3dg may have bound
another domain of hCR2 or a neo epitope generated in the hybrid CR2
Fig. 5. hCR2 (SCR 1–4)-Fc construct but not mCR2-Fc binds readily to immobilized serum-derived hC3d.
Surface plasmon resonance sensorgrams demonstrating the association and dissociation of hCR2 SCR1-4–Fc (a), mCR2 SCR1-4 − Fc (b), and HEL − Fc (c) to immobilized monomeric
native human C3d (imob.hC3d). Nanomolar concentrations of injected analyte are indicated at the right hand side of each sensorgram. Lines indicated are the normalized experimental
sensorgram kinetic data. Steady state affinity graphs (d–i) were generated by plotting the concentrations of analyte flowed over the surface (coated with immobilized recombinant native
hC3d or hC3dg Fc fusions or Cys to Ser (donated by s) variants of those molecules, as indicated, at between 94.3–96.2 RU of ligand) against the equilibrium response Req (in absorbance
units, AU) of hCR2-Fc. The slope of each curve indicates higher or lower affinity of the analyte to the ligand. Calculated KD values are indicated in graphs. c2 values showed that the curve
fit described the data well (see Supplemental Table 1). Data shown is representative of triplicates.
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protein or the glutaraldehyde cross-linked pC3dg, in any cases both
proteins were essentially synthetic constructs and not in their native
conformation. This does not completely explain the findings by Molina
et al., although the affinity analysis in this study was also carried out
with a similar glutaraldehyde cross-linked human C3d, their initial
binding studies used erythrocytes coated with human complement
components and where blocked by an antibody (7G6) known to block
mouse C3d interactions (Molina et al., 1991; Kinoshita et al., 1990).
However, these data are in conflict with the earlier work using anti-
body-complement based rosette assays with mouse splenocytes or
mouse B cell lines which indicated little or significantly reduced in-
teraction between human C3d and mouse complement receptors
(Dierich et al., 1974), (Fingeroth et al., 1989).
A second equally surprising finding from our study is that hC3d
binding to hCR2 expressed by mouse B cells was only evident when the
B cells were isolated from mice lacking C3. This strongly suggests that
mC3d successfully competes with hC3d for binding to hCR2. This was
supported by our SPR binding data (Fig. 5i). Thus, these findings sug-
gest that use of transgenic mice expressing hCR2 for the testing of hC3d-
based molecular adjuvants is severely limited.
The oligomerisation domain on the complement regulator C4BP
(Scharfstein et al., 1978) has previously been exploited to increase
valency of either recombinant antibodies (Libyh et al., 1997; Oudin
et al., 2000) or a viral receptor (Christiansen et al., 2000). This led us to
conceive an oligomeric vaccine structure based on C4BP that would
have three functionally established benefits. Firstly, it would act as
oligomeric antigen carrier, secondly, by containing hC3d, it would
target B cells (via CR2) and thirdly, via the C4BP oligomerisation do-
main (the last 60 C-terminal amino acids of the C4BP alpha chain), it
would also act as a T cell adjuvant (Forbes et al., 2012). The combi-
nation of the C3d/B cell interaction with the T cell adjuvant effects of
the oligomer compound was thus predicted to enhance immunity to the
TTCF test antigen significantly compared to immunizing animals with
antigen alone. However, we found no evidence of any adjuvant effect
when measuring anti-TTCF specific antibodies. This also suggests the
oligomerisation domain of hC4BP does not provide CD4+ T cell help for
any anti-TTCF B cells in the mouse. Furthermore, no advantage of oligo-
antigen valency over monomeric antigen was realized, although this
was likely compounded by the lack of interaction between hC3d and m
(or) hCR2.
The full testing of these oligomeric hC3d antigen compounds in the
recently generated hCR2 BAC mice (Kulik et al., 2011) crossed onto the
Fig. 6. Recombinant hC3d-TTCF-hC4BP binding to hCR2 expressed on transgenic mouse B cells is influenced by the presence of mC3.
Isolated splenocytes (genotypes indicated above) were stained with (a) biotinylated anti-hCR2 mAb 171 (x axis) and anti-B220-APC to identify B cells (y axis) or (b) biotinylated hC3d-
TTCF-hC4BP and anti-B220-APC followed by SA-PE. In addition splenocytes from hCR tg. C3−/−(Cr2+/+) were also stained with biotinylated hC3d-TTCF-hC4BP and anti-B220-APC
followed by SA-PE, in the presence unlabeled mAb 171 (lower panel). Panels shown are representative of three separate experiments.
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C3−/− background would be possible given time. However, these ex-
periments will be hampered by the loss of endogenous C3 to drive and
support the immune response and therefore give a true idea of how that
will translate to the clinical setting that these pre-clinical studies are
supposed to emulate. We concede that only construction of mC3d fused
to mC4BP constructs will allow the adjuvant capabilities of similar
oligomeric C3d compounds to be fully tested in mouse models. This
remains an important line of investigation as there are still many un-
knowns regarding the mode of action of C3d as an adjuvant. The linear
trimer construct of C3d has been shown to be an effective stimulator of
B cell responses but monomeric C3d-Ag is considered im-
munosuppressive (Dempsey et al., 1996). Thus, would an arrayed C3d
structure function as a group of monomers in this context or act similar
to the linear trimer? Potentially, C3d-containing multimers may also
result in reduced immune response due to excessive CR2 cross-linking
that has been reported with the use of high doses of C3dg-streptavidin
complexes (Lee et al., 2005).
In summary, these experiments clearly demonstrate that hC3d does
not bind to mCR2 as previously reported, while mC3d does bind hCR2
with an increased affinity to that measured for hC3d. Importantly we
also demonstrate for the first time that even following the replacement
of mCR2 with the hCR2 homologue in transgenic animals no hC3/hCR2
binding is seen in the present of mC3. These 2 new findings severely
hamper the testing of novel strategies to improve the efficiencies of
hC3d-containing recombinant adjuvants in mice. Importantly these
studies thus highlight the importance of extensive testing of candidate
C3-based vaccines and that, even when attempts are made to maximize
species conservation in animal models, considerable care needs to be
taken when analyzing cross species receptor/ligand interactions.
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